Equities

Chemclin Diagnostics Co Ltd

688468:SHH

Chemclin Diagnostics Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)7.11
  • Today's Change-0.19 / -2.60%
  • Shares traded8.09m
  • 1 Year change-37.69%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments919985925
Total Receivables, Net534238
Total Inventory111113122
Prepaid expenses20265.96
Other current assets, total------
Total current assets1,1031,1651,091
Property, plant & equipment, net495223158
Goodwill, net154154154
Intangibles, net452914
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets1,8211,5911,431
LIABILITIES
Accounts payable906822
Accrued expenses223924
Notes payable/short-term debt000
Current portion long-term debt/capital leases6.661111
Other current liabilities, total758064
Total current liabilities194197122
Total long term debt2281.5713
Total debt2351225
Deferred income tax9.681212
Minority interest------
Other liabilities, total----5.00
Total liabilities432211152
SHAREHOLDERS EQUITY
Common stock401401401
Additional paid-in capital565565547
Retained earnings (accumulated deficit)423415330
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,3891,3811,279
Total liabilities & shareholders' equity1,8211,5911,431
Total common shares outstanding401401401
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.